Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.

Abstract

Ascorbic acid metabolism is associated with a number of mechanisms known to be involved in host resistance to malignant disease. Cancer patients are significantly depleted of ascorbic acid, and in our opinion this demonstrable biochemical characteristic indicates a substantially increased requirement and utilization of this substance to potentiate these various host resistance factors.The results of a clinical trial are presented in which 100 terminal cancer patients were given supplemental ascorbate as part of their routine management. Their progress is compared to that of 1000 similar patients treated identically, but who received no supplementa ascorbate. The mean survival time is more than 4.2 times as great for the ascorbate subjects (more than 210 days) as for the controls (50 days) Analysis of the survival-time curves indicates that deaths occur for about 90% of the ascorbatetreated patients at one-third the rate for the controls and that the other 10% have a much greater survival time, averaging more than 20 times that for the controls.The results clearly indicate that this simple and safe form of medication is of definite value in the treatment of patients with advanced cancer.

Vitamin C in Disease Prevention and Cure: An Overview

“…It was demonstrated by Cameron et al [133][134][135], that high-dose vitamin C improved the survival of patients with terminal cancer. However, the first documented study in which vitamin C was administered to cancer patients was carried out in the 1970s, by Pauling and Cameron.…”

The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity

“…Clarifying the effects of Vc on human health is important because large doses are consumed (orally) by countless individuals worldwide without prescription and administered (most frequently intravenously) by thousands of alternative practitioners to patients with advanced cancer (52). The controversy regarding Vc and human health started in the 1970s with the debated anticancer claims by Pauling and Cameron (17)(18)(19)(20). More recent studies have demonstrated that a possible reason for the discrepancies between independent reports is the route of administration (oral plus intravenous versus oral only) (21,22).…”

“…Pauling asserted that megadose Vc could combat a wide range of human diseases, in particular cancer (16). He and Cameron performed clinical trials showing a significant efficacy of intravenous Vc in delaying the death of patients with terminal cancer (17,18). However, these results were heavily criticized after subsequent studies in the Mayo Clinic failed to reproduce this outcome with oral administration (19,20).…”

Two Grams BID Is an Oral Dosage of Vitamin C to Reduce the Risk of Recurrence of Superficial Bladder Carcinoma

“…Many patients were given 10 g daily orally, but a variety of other AA treatments were used. Copyright 1976 National Academy of Sciences, USA [4]. Relationship of dose of AA to total urinary excretion.…”